Cost-effectiveness of 12-month therapeutic assertive community treatment as part of integrated care versus standard care in patients with schizophrenia treated with quetiapine immediate release (ACCESS trial)

Journal of Clinical Psychiatry

Volumn 73, Issue 3, 2012, Pages

  Karow, Anne ^a   Reimer, Jens ^a   König, Hans Helmut ^a   Heider, Dirk ^a,c   Bock, Thomas ^a   Huber, Christian ^a   Schöttle, Daniel ^a   Meister, Klara ^a   Rietschel, Liz ^a   Ohm, Gunda ^a   Schulz, Holger ^a   Naber, Dieter ^a   Schimmelmann, Benno G ^b   Lambert, Martin ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

QUETIAPINE;

ADULT; AGED; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; COMORBIDITY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE DURATION; DISEASE SEVERITY; EDUCATIONAL STATUS; EMPLOYMENT STATUS; FAMILY HISTORY; FEMALE; FUNCTIONAL ASSESSMENT; FUNCTIONAL STATUS; HEALTH CARE COST; HUMAN; INTEGRATED HEALTH CARE SYSTEM; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SCHIZOPHRENIA; SUBSTANCE ABUSE; THERAPEUTIC COMMUNITY; TREATMENT DURATION;

EID: 84859149507     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.11m06875     Document Type: Article

References (36)

1. Cannon M, Caspi A, Moffitt TE, et al. Evidence for early-childhood, pan-developmental impairment specific to schizophreniform disorder: results from a longitudinal birth cohort. Arch Gen Psychiatry. 2002;59(5):449-456. doi:10.101/archpsyc.59.5.49 PubMed (Pubitemid 34477681)
2. Conus P, Cotton S, Schimmelmann B, et al. Pretreatment and outcome correlates of sexual and physical trauma in an epidemiological cohort of first-episode psychosis patients. Schizophr Bull. 2010;36(6):1105-1114. PubMed doi:10.1093/schbul/sbp09
3. Kim-Cohen J, Caspi A, Moffitt TE, et al. Prior juvenile diagnoses in adults with mental disorder: developmental follow-back of a prospectivelongitudinal cohort. Arch Gen Psychiatry. 2003;60(7):709-717. doi:10.101/archpsyc.60.7.709 PubMed (Pubitemid 36818633)
4. Marshall M, Lewis S, Lockwood A, et al. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch Gen Psychiatry. 2005;62(9):975-983. doi:10.101/archpsyc. 62.9.975 PubMed (Pubitemid 41248376)
5. Demjaha A, Morgan K, Morgan C, et al. Combining dimensional and categorical representation of psychosis: the way forward for DSM-V and ICD-11? Psychol Med. 2009;39(12):1943-1955. doi:10.1017/S032917090651 PubMed
6. Krabbendam L, Arts B, van Os J, et al. Cognitive functioning in patients with schizophrenia and bipolar disorder: a quantitative review. Schizophr Res. 2005;80(2-3):137-149. doi:10.1016/j.schres.205.08.04 PubMed (Pubitemid 41713640)
7. Lambert M, Naber D, eds. Current Schizophrenia. 2nd ed. London, England: Current Medicine Group; 2009:1-156.
8. Velligan DI, Weiden PJ, Sajatovic M, et al Expert Consensus Panel on Adherence Problems in Serious and Persistent Mental Illness. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009;70(suppl 4):1-46, quiz 47-48. PubMed
9. Fleischhacker WW, Cetkovich-Bakmas M, De Hert M, et al. Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges. J Clin Psychiatry. 2008;69(4):514-519. doi:10.408/JCP. v69n0401 PubMed (Pubitemid 351792324)
10. Lambert M, Bock T, Schöttle D, et al. Assertive community treatment aspart of integrated care versus standard care: a 12-month trial in patients with first- and multiple-episode schizophrenia spectrum disorders treated with quetiapine immediate release (ACCESS trial). J Clin Psychiatry. 2010;71(10):1313-1323. doi:10.408/JCP.09m0513yel PubMed
11. Stein LI, Test MA. Alternative to mental hospital treatment, 1: conceptual model, treatment program, and clinical evaluation. Arch Gen Psychiatry. 1980;37(4):392-397. PubMed (Pubitemid 10100566)
12. Marshall M, Lockwood A. Assertive community treatment for people with severe mental disorders (review). Cochrane Database Syst Rev. 1998;2:CD001089.
13. Teague GB, Bond GR, Drake RE. Program fidelity in assertive community treatment: development and use of a measure. Am J Orthopsychiatry. 1998;68(2):216-232. doi:10.1037/h08031 PubMed (Pubitemid 28215538)
14. Assertive Community Treatment Association (ACTA). http://www. actassociation.org. 2007.
15. Sytema S, Wunderink L, Bloemers W, et al. Assertive community treatment in the Netherlands: a randomized controlled trial. Acta Psychiatr Scand. 2007;116(2):105-112. doi:10.1/j.160-047.207.01021.x PubMed (Pubitemid 47076274)
16. Killaspy H, Bebbington P, Blizard R, et al. The REACT study: randomised evaluation of assertive community treatment in north London. BMJ. 2006;332(7545):815-820. doi:10.136/bmj.3873.51832.7C PubMed
17. Gold M, Siegel J, Russell L, et al. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
18. Drummond MF, Sculpher M, Torrance G, et al. Methods for the Economic Evaluation of Health Care Programmes. 3rd ed: New York, NY: Oxford University Press; 2005.
19. Hirth RA, Chernew ME, Miller E, et al. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making. 2000;20(3): 332-342. doi:10.17/0272989X020310 PubMed (Pubitemid 30479101)
20. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association, 2000.
21. Ventura J, Liberman RP, Green MF, et al. Training and quality assurance with the Structured Clinical Interview for DSM-IV (SCID-I/P). Psychiatry Res. 1998;79(2):163-173. doi:10.1016/S0165-1781(98)038-9 PubMed (Pubitemid 28308489)
22. Bertelsen M, Jeppesen P, Petersen L, et al. Five-year follow-up of arandomized multicenter trial of intensive early intervention vs standard treatment for patients with a first episode of psychotic illness: the OPUS trial. Arch Gen Psychiatry. 2008;65(7):762-771. doi:10.101/archpsyc.65.7.762 PubMed (Pubitemid 351957702)
23. Conus P, Cotton S, Schimmelmann B, et al. The First-Episode Psychosis Outcome Study: premorbid and baseline characteristics of an epidemiological cohort of 661 first-episode psychosis patients. Early Interv Psychiatry. 2007;1:191-200. doi:10.1/j.1751-7893.207.026.x
24. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276. PubMed (Pubitemid 18039085)
25. Guy W. Clinical global impression. In: Guy W, ed. ECDEU Assessment Manual for Psychopharmacology, revised. Rockville, MI: National Institute of Mental Health;1976:217-222.
26. Brooks R, Rabin R, De Charro F. The Measurement and Valuation of Health Status Using EQ-5D: A European Perspective. New York, NY: Kluwer Academic Publishers; 2003.
27. Ritsner M, Kurs R, Gibel A, et al. Validity of an abbreviated quality of life enjoyment and satisfaction questionnaire (Q-LES-Q-18) for schizophrenia, schizoaffective, and mood disorder patients. Qual Life Res. 2005;14(7):1693- 1703. doi:10.107/s136-05-2816-9 PubMed (Pubitemid 40978478)
28. Naber D, Moritz S, Lambert M, et al. Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr Res. 2001;50(1-2):79-88. doi:10.1016/S0920-964(0)016-3 PubMed (Pubitemid 32510889)
29. Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35(11):1095-1108. doi:10.1097/05650-19710-02 PubMed (Pubitemid 127453463)
30. König HH, Roick C, Angermeyer MC. Validity of the EQ-5D in assessing and valuing health status in patients with schizophrenic, schizotypal or delusional disorders. Eur Psychiatry. 2007;22(3): 177-187. doi:10.1016/j.eurpsy. 206.08.04 PubMed (Pubitemid 46507734)
31. Krauth C, Hessel F, Hansmeier T, et al. Empirical standard costs for health economic evaluation in Germany-a proposal by the working group methods in health economic evaluation [in German]. Gesundheitswesen. 2005;67(10):736-746. PubMed doi:10.105/s-205-858698
32. Rote Liste-Arzneimittelverzeichnis für Deutschland. Frankfurt/Main, Germany: Rote Liste Service GmbH; 2007.
33. EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy. 1990;16(3):199-208. doi:10.1016/0168-8510(90)90421-9 PubMed
34. Kind P. Guidelines for value sets in economic and non-economic studies using EQ-5D. In: Brooks R, Rabin R, De Charro F, eds. The Measurement and Valuation of Health Status Using EQ-5D: A European Perspective. New York, NY: Kluwer; 2003.
35. McCrone P, Killaspy H, Bebbington P, et al. The REACT study: cost-effectiveness analysis of assertive community treatment in north London. Psychiatr Serv. 2009;60(7):908-913. doi:10.176/api.ps.60.7.908 PubMed
36. Richardson G, Manca A. Calculation of quality adjusted life years in the published literature: a review of methodology and transparency. Health Econ. 2004;13(12):1203-1210. doi:10.102/hec.901 PubMed (Pubitemid 40017242)